vs
Encompass Health Corp（EHC）とEnova International, Inc.（ENVA）の財務データ比較。上の社名をクリックして会社を切り替えられます
Encompass Health Corpの直近四半期売上が大きい（$1.5B vs $875.1M、Enova International, Inc.の約1.8倍）。Enova International, Inc.の純利益率が高く（10.4% vs 9.5%、差は1.0%）。Enova International, Inc.の前年同期比売上増加率が高い（17.4% vs 9.9%）。過去8四半期でEnova International, Inc.の売上複合成長率が高い（18.0% vs 8.3%）
エンコンパスヘルスコーポレーション（旧Amcare、HealthSouth）は米国アラバマ州バーミンガムに本社を置く米国最大の入院リハビリサービス事業者で、39州とプエルトリコに173の入院リハビリ病院を展開し、脳卒中や神経疾患、心肺疾患、脳損傷から回復中の患者に専門的な治療とケアを提供している。
エノバ・インターナショナルはグローバルなフィンテック企業で、短期消費者ローンや中小企業向け融資などのオンライン金融ソリューションを提供しています。主に北米、南米、欧州の顧客を対象に、高度なデータ分析で信用力を評価し、従来金融でアクセスしにくい層に適した商品を届けています。
EHC vs ENVA — 直接比較
損益計算書 — Q4 FY2025 vs Q1 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $1.5B | $875.1M |
| 純利益 | $146.1M | $91.1M |
| 粗利率 | — | — |
| 営業利益率 | 16.7% | 23.7% |
| 純利益率 | 9.5% | 10.4% |
| 売上前年比 | 9.9% | 17.4% |
| 純利益前年比 | 20.8% | 24.9% |
| EPS（希薄化後） | $1.43 | $3.46 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | — | $875.1M | ||
| Q4 25 | $1.5B | $839.4M | ||
| Q3 25 | $1.5B | $802.7M | ||
| Q2 25 | $1.5B | $764.0M | ||
| Q1 25 | $1.5B | $745.5M | ||
| Q4 24 | $1.4B | $729.6M | ||
| Q3 24 | $1.4B | $689.9M | ||
| Q2 24 | $1.3B | $628.4M |
| Q1 26 | — | $91.1M | ||
| Q4 25 | $146.1M | $79.0M | ||
| Q3 25 | $126.5M | $80.3M | ||
| Q2 25 | $142.1M | $76.1M | ||
| Q1 25 | $151.5M | $72.9M | ||
| Q4 24 | $120.9M | $63.7M | ||
| Q3 24 | $108.2M | $43.4M | ||
| Q2 24 | $114.1M | $53.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | 57.4% | ||
| Q2 25 | — | 57.8% | ||
| Q1 25 | — | 57.2% | ||
| Q4 24 | — | 56.6% | ||
| Q3 24 | — | 58.0% | ||
| Q2 24 | — | 58.9% |
| Q1 26 | — | 23.7% | ||
| Q4 25 | 16.7% | 22.2% | ||
| Q3 25 | 14.9% | 24.5% | ||
| Q2 25 | 16.2% | 24.1% | ||
| Q1 25 | 16.4% | 23.1% | ||
| Q4 24 | 14.3% | 21.3% | ||
| Q3 24 | 13.6% | 22.3% | ||
| Q2 24 | 14.3% | 23.1% |
| Q1 26 | — | 10.4% | ||
| Q4 25 | 9.5% | 9.4% | ||
| Q3 25 | 8.6% | 10.0% | ||
| Q2 25 | 9.7% | 10.0% | ||
| Q1 25 | 10.4% | 9.8% | ||
| Q4 24 | 8.6% | 8.7% | ||
| Q3 24 | 8.0% | 6.3% | ||
| Q2 24 | 8.8% | 8.6% |
| Q1 26 | — | $3.46 | ||
| Q4 25 | $1.43 | $2.94 | ||
| Q3 25 | $1.24 | $3.03 | ||
| Q2 25 | $1.39 | $2.86 | ||
| Q1 25 | $1.48 | $2.69 | ||
| Q4 24 | $1.18 | $2.29 | ||
| Q3 24 | $1.06 | $1.57 | ||
| Q2 24 | $1.12 | $1.93 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $72.2M | $96.1M |
| 総負債低いほど良い | $2.4B | $4.8B |
| 株主資本純資産 | $2.4B | — |
| 総資産 | $7.1B | $6.9B |
| 負債/資本比率低いほどレバレッジが低い | 1.00× | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | $96.1M | ||
| Q4 25 | $72.2M | $71.7M | ||
| Q3 25 | $48.7M | $53.6M | ||
| Q2 25 | $99.1M | $55.6M | ||
| Q1 25 | $95.8M | $55.5M | ||
| Q4 24 | $85.4M | $73.9M | ||
| Q3 24 | $147.8M | $67.5M | ||
| Q2 24 | $154.4M | $60.1M |
| Q1 26 | — | $4.8B | ||
| Q4 25 | $2.4B | $4.5B | ||
| Q3 25 | $2.4B | $4.1B | ||
| Q2 25 | $2.3B | $4.0B | ||
| Q1 25 | $2.3B | $3.8B | ||
| Q4 24 | $2.4B | $3.6B | ||
| Q3 24 | $2.3B | $3.3B | ||
| Q2 24 | $2.7B | $3.2B |
| Q1 26 | — | — | ||
| Q4 25 | $2.4B | $1.3B | ||
| Q3 25 | $2.4B | $1.3B | ||
| Q2 25 | $2.3B | $1.2B | ||
| Q1 25 | $2.2B | $1.2B | ||
| Q4 24 | $2.1B | $1.2B | ||
| Q3 24 | $2.0B | $1.2B | ||
| Q2 24 | $1.8B | $1.1B |
| Q1 26 | — | $6.9B | ||
| Q4 25 | $7.1B | $6.5B | ||
| Q3 25 | $6.9B | $6.0B | ||
| Q2 25 | $6.8B | $5.7B | ||
| Q1 25 | $6.6B | $5.5B | ||
| Q4 24 | $6.5B | $5.3B | ||
| Q3 24 | $6.5B | $5.0B | ||
| Q2 24 | $6.4B | $4.8B |
| Q1 26 | — | — | ||
| Q4 25 | 1.00× | 3.37× | ||
| Q3 25 | 1.01× | 3.20× | ||
| Q2 25 | 1.02× | 3.23× | ||
| Q1 25 | 1.08× | 3.14× | ||
| Q4 24 | 1.14× | 2.98× | ||
| Q3 24 | 1.20× | 2.79× | ||
| Q2 24 | 1.46× | 2.78× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $346.0M | — |
| フリーキャッシュフロー営業CF - 設備投資 | $116.7M | — |
| FCFマージンFCF / 売上 | 7.6% | — |
| 設備投資強度設備投資 / 売上 | 14.8% | — |
| キャッシュ転換率営業CF / 純利益 | 2.37× | — |
| 直近12ヶ月FCF直近4四半期 | $439.2M | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | — | ||
| Q4 25 | $346.0M | $498.8M | ||
| Q3 25 | $270.8M | $481.8M | ||
| Q2 25 | $270.2M | $447.4M | ||
| Q1 25 | $288.6M | $391.1M | ||
| Q4 24 | $278.8M | $430.5M | ||
| Q3 24 | $267.8M | $398.6M | ||
| Q2 24 | $217.4M | $360.9M |
| Q1 26 | — | — | ||
| Q4 25 | $116.7M | $487.1M | ||
| Q3 25 | $83.7M | $470.5M | ||
| Q2 25 | $113.3M | $436.1M | ||
| Q1 25 | $125.5M | $378.3M | ||
| Q4 24 | $80.1M | $420.3M | ||
| Q3 24 | $120.3M | $387.6M | ||
| Q2 24 | $60.5M | $349.9M |
| Q1 26 | — | — | ||
| Q4 25 | 7.6% | 58.0% | ||
| Q3 25 | 5.7% | 58.6% | ||
| Q2 25 | 7.8% | 57.1% | ||
| Q1 25 | 8.6% | 50.7% | ||
| Q4 24 | 5.7% | 57.6% | ||
| Q3 24 | 8.9% | 56.2% | ||
| Q2 24 | 4.6% | 55.7% |
| Q1 26 | — | — | ||
| Q4 25 | 14.8% | 1.4% | ||
| Q3 25 | 12.7% | 1.4% | ||
| Q2 25 | 10.8% | 1.5% | ||
| Q1 25 | 11.2% | 1.7% | ||
| Q4 24 | 14.1% | 1.4% | ||
| Q3 24 | 10.9% | 1.6% | ||
| Q2 24 | 12.1% | 1.8% |
| Q1 26 | — | — | ||
| Q4 25 | 2.37× | 6.32× | ||
| Q3 25 | 2.14× | 6.00× | ||
| Q2 25 | 1.90× | 5.87× | ||
| Q1 25 | 1.90× | 5.36× | ||
| Q4 24 | 2.31× | 6.76× | ||
| Q3 24 | 2.48× | 9.18× | ||
| Q2 24 | 1.91× | 6.70× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
EHC
| Medicare | $1.0B | 66% |
| Medicare Advantage | $243.1M | 16% |
| Managed Care | $160.7M | 10% |
| Medicaid | $47.0M | 3% |
| Other Income Source | $44.8M | 3% |
| Other Thirdparty Payors | $11.2M | 1% |
| Workers Compensation | $7.6M | 0% |
| Patients | $4.6M | 0% |
ENVA
セグメントデータなし
